Stereotactic radiotherapy and oligometastases – Authors' reply
Regarding the so-called missed opportunity and the potential effect of our study on recruitment for randomised controlled trials, we note that the Commissioning through Evaluation programme prepared 17 stereotactic ablative radiotherapy centres across the UK to recruit patients into the CORE trial (...
Gespeichert in:
| Veröffentlicht in: | The lancet oncology 2021-04, Vol.22 (4), p.e133-e133 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e133 |
|---|---|
| container_issue | 4 |
| container_start_page | e133 |
| container_title | The lancet oncology |
| container_volume | 22 |
| creator | Chalkidou, Anastasia Patrick, Hannah Hatton, Matthew Q Hawkins, Maria A van As, Nicholas |
| description | Regarding the so-called missed opportunity and the potential effect of our study on recruitment for randomised controlled trials, we note that the Commissioning through Evaluation programme prepared 17 stereotactic ablative radiotherapy centres across the UK to recruit patients into the CORE trial (NCT02759783) via its Radiotherapy Trials Quality Assurance process. There are other relevant ongoing randomised controlled trials, such as four phase 3 randomised controlled trials for oligometastatic prostate cancer alone.2 In the meantime, careful patient selection by experienced multi-disciplinary teams remains essential to ensure that only patients who are likely to benefit from stereotactic ablative radiotherapy receive this treatment. HP reports working for the UK National Institute for Health and Care Excellence during the conduct of the study, which was commissioned by the UK National Health Service England to manage the Commissioning through Evaluation project. |
| doi_str_mv | 10.1016/S1470-2045(21)00144-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2506716821</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1470204521001443</els_id><sourcerecordid>2506716821</sourcerecordid><originalsourceid>FETCH-LOGICAL-c308t-565519c988ff2298d98308e2a934d6000579ae608a1e68385d69963822b3de433</originalsourceid><addsrcrecordid>eNqFkMtKAzEUhoMoVquPoAy4UBejuU-y0lK8QcFFdR3SyRk7pW3GJBW68x18Q5_E6UW3QuCEw3f-w_kQOiH4imAir4eEFzinmIsLSi4xJpznbAcdtG2eC67U7vq_QTroMMZJCxUEi33UYazQnBJygG6HCQL4ZMtUl1mwrvZpDME2y8zOXean9ZufQbKxfRCz78-vrLdIYx_ieRagmS6P0F5lpxGOt7WLXu_vXvqP-eD54anfG-QlwyrlQgpBdKmVqipKtXJatX2gVjPuJMZYFNqCxMoSkIop4aTWkilKR8wBZ6yLzja5TfDvC4jJTPwizNuVhgosCyIVJS0lNlQZfIwBKtOEembD0hBsVt7M2ptZSTGUmLU3s0o_3aYvRjNwf1O_olrgZgNAe-NHDcHEsoZ5Ca4OUCbjfP3Pih8uSHtQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2506716821</pqid></control><display><type>article</type><title>Stereotactic radiotherapy and oligometastases – Authors' reply</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><source>ProQuest Central UK/Ireland</source><creator>Chalkidou, Anastasia ; Patrick, Hannah ; Hatton, Matthew Q ; Hawkins, Maria A ; van As, Nicholas</creator><creatorcontrib>Chalkidou, Anastasia ; Patrick, Hannah ; Hatton, Matthew Q ; Hawkins, Maria A ; van As, Nicholas ; study authors ; study authors</creatorcontrib><description>Regarding the so-called missed opportunity and the potential effect of our study on recruitment for randomised controlled trials, we note that the Commissioning through Evaluation programme prepared 17 stereotactic ablative radiotherapy centres across the UK to recruit patients into the CORE trial (NCT02759783) via its Radiotherapy Trials Quality Assurance process. There are other relevant ongoing randomised controlled trials, such as four phase 3 randomised controlled trials for oligometastatic prostate cancer alone.2 In the meantime, careful patient selection by experienced multi-disciplinary teams remains essential to ensure that only patients who are likely to benefit from stereotactic ablative radiotherapy receive this treatment. HP reports working for the UK National Institute for Health and Care Excellence during the conduct of the study, which was commissioned by the UK National Health Service England to manage the Commissioning through Evaluation project.</description><identifier>ISSN: 1470-2045</identifier><identifier>EISSN: 1474-5488</identifier><identifier>DOI: 10.1016/S1470-2045(21)00144-3</identifier><identifier>PMID: 33794211</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Clinical trials ; Humans ; Neoplasms ; Prospective Studies ; Prostate cancer ; Quality assurance ; Radiation therapy ; Radiosurgery - adverse effects ; Registries</subject><ispartof>The lancet oncology, 2021-04, Vol.22 (4), p.e133-e133</ispartof><rights>2021 Elsevier Ltd</rights><rights>2021. Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c308t-565519c988ff2298d98308e2a934d6000579ae608a1e68385d69963822b3de433</citedby><cites>FETCH-LOGICAL-c308t-565519c988ff2298d98308e2a934d6000579ae608a1e68385d69963822b3de433</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2506716821?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3548,27922,27923,45993,64383,64387,72239</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33794211$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chalkidou, Anastasia</creatorcontrib><creatorcontrib>Patrick, Hannah</creatorcontrib><creatorcontrib>Hatton, Matthew Q</creatorcontrib><creatorcontrib>Hawkins, Maria A</creatorcontrib><creatorcontrib>van As, Nicholas</creatorcontrib><creatorcontrib>study authors</creatorcontrib><creatorcontrib>study authors</creatorcontrib><title>Stereotactic radiotherapy and oligometastases – Authors' reply</title><title>The lancet oncology</title><addtitle>Lancet Oncol</addtitle><description>Regarding the so-called missed opportunity and the potential effect of our study on recruitment for randomised controlled trials, we note that the Commissioning through Evaluation programme prepared 17 stereotactic ablative radiotherapy centres across the UK to recruit patients into the CORE trial (NCT02759783) via its Radiotherapy Trials Quality Assurance process. There are other relevant ongoing randomised controlled trials, such as four phase 3 randomised controlled trials for oligometastatic prostate cancer alone.2 In the meantime, careful patient selection by experienced multi-disciplinary teams remains essential to ensure that only patients who are likely to benefit from stereotactic ablative radiotherapy receive this treatment. HP reports working for the UK National Institute for Health and Care Excellence during the conduct of the study, which was commissioned by the UK National Health Service England to manage the Commissioning through Evaluation project.</description><subject>Clinical trials</subject><subject>Humans</subject><subject>Neoplasms</subject><subject>Prospective Studies</subject><subject>Prostate cancer</subject><subject>Quality assurance</subject><subject>Radiation therapy</subject><subject>Radiosurgery - adverse effects</subject><subject>Registries</subject><issn>1470-2045</issn><issn>1474-5488</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqFkMtKAzEUhoMoVquPoAy4UBejuU-y0lK8QcFFdR3SyRk7pW3GJBW68x18Q5_E6UW3QuCEw3f-w_kQOiH4imAir4eEFzinmIsLSi4xJpznbAcdtG2eC67U7vq_QTroMMZJCxUEi33UYazQnBJygG6HCQL4ZMtUl1mwrvZpDME2y8zOXean9ZufQbKxfRCz78-vrLdIYx_ieRagmS6P0F5lpxGOt7WLXu_vXvqP-eD54anfG-QlwyrlQgpBdKmVqipKtXJatX2gVjPuJMZYFNqCxMoSkIop4aTWkilKR8wBZ6yLzja5TfDvC4jJTPwizNuVhgosCyIVJS0lNlQZfIwBKtOEembD0hBsVt7M2ptZSTGUmLU3s0o_3aYvRjNwf1O_olrgZgNAe-NHDcHEsoZ5Ca4OUCbjfP3Pih8uSHtQ</recordid><startdate>202104</startdate><enddate>202104</enddate><creator>Chalkidou, Anastasia</creator><creator>Patrick, Hannah</creator><creator>Hatton, Matthew Q</creator><creator>Hawkins, Maria A</creator><creator>van As, Nicholas</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>202104</creationdate><title>Stereotactic radiotherapy and oligometastases – Authors' reply</title><author>Chalkidou, Anastasia ; Patrick, Hannah ; Hatton, Matthew Q ; Hawkins, Maria A ; van As, Nicholas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c308t-565519c988ff2298d98308e2a934d6000579ae608a1e68385d69963822b3de433</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Clinical trials</topic><topic>Humans</topic><topic>Neoplasms</topic><topic>Prospective Studies</topic><topic>Prostate cancer</topic><topic>Quality assurance</topic><topic>Radiation therapy</topic><topic>Radiosurgery - adverse effects</topic><topic>Registries</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chalkidou, Anastasia</creatorcontrib><creatorcontrib>Patrick, Hannah</creatorcontrib><creatorcontrib>Hatton, Matthew Q</creatorcontrib><creatorcontrib>Hawkins, Maria A</creatorcontrib><creatorcontrib>van As, Nicholas</creatorcontrib><creatorcontrib>study authors</creatorcontrib><creatorcontrib>study authors</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>The lancet oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chalkidou, Anastasia</au><au>Patrick, Hannah</au><au>Hatton, Matthew Q</au><au>Hawkins, Maria A</au><au>van As, Nicholas</au><aucorp>study authors</aucorp><aucorp>study authors</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Stereotactic radiotherapy and oligometastases – Authors' reply</atitle><jtitle>The lancet oncology</jtitle><addtitle>Lancet Oncol</addtitle><date>2021-04</date><risdate>2021</risdate><volume>22</volume><issue>4</issue><spage>e133</spage><epage>e133</epage><pages>e133-e133</pages><issn>1470-2045</issn><eissn>1474-5488</eissn><abstract>Regarding the so-called missed opportunity and the potential effect of our study on recruitment for randomised controlled trials, we note that the Commissioning through Evaluation programme prepared 17 stereotactic ablative radiotherapy centres across the UK to recruit patients into the CORE trial (NCT02759783) via its Radiotherapy Trials Quality Assurance process. There are other relevant ongoing randomised controlled trials, such as four phase 3 randomised controlled trials for oligometastatic prostate cancer alone.2 In the meantime, careful patient selection by experienced multi-disciplinary teams remains essential to ensure that only patients who are likely to benefit from stereotactic ablative radiotherapy receive this treatment. HP reports working for the UK National Institute for Health and Care Excellence during the conduct of the study, which was commissioned by the UK National Health Service England to manage the Commissioning through Evaluation project.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>33794211</pmid><doi>10.1016/S1470-2045(21)00144-3</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1470-2045 |
| ispartof | The lancet oncology, 2021-04, Vol.22 (4), p.e133-e133 |
| issn | 1470-2045 1474-5488 |
| language | eng |
| recordid | cdi_proquest_journals_2506716821 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present); ProQuest Central UK/Ireland |
| subjects | Clinical trials Humans Neoplasms Prospective Studies Prostate cancer Quality assurance Radiation therapy Radiosurgery - adverse effects Registries |
| title | Stereotactic radiotherapy and oligometastases – Authors' reply |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T13%3A08%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Stereotactic%20radiotherapy%20and%20oligometastases%20%E2%80%93%20Authors'%20reply&rft.jtitle=The%20lancet%20oncology&rft.au=Chalkidou,%20Anastasia&rft.aucorp=study%20authors&rft.date=2021-04&rft.volume=22&rft.issue=4&rft.spage=e133&rft.epage=e133&rft.pages=e133-e133&rft.issn=1470-2045&rft.eissn=1474-5488&rft_id=info:doi/10.1016/S1470-2045(21)00144-3&rft_dat=%3Cproquest_cross%3E2506716821%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2506716821&rft_id=info:pmid/33794211&rft_els_id=S1470204521001443&rfr_iscdi=true |